HER2-Positive Breast Cancer
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease. A year of treatment with the antibody-drug conjugate trastuzumab emtansine effectively prevents HER2-positive BC ... Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer. The HER2DX ERBB2 mRNA score was significantly associated with improved survival in patients with metastatic HER2+ BC. Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer. CNS radiotherapy with pyrotinib and capecitabine improves CNS progression in breast cancer patients with brain metastases. Will HER2CLIMB-02 study data impact the breast cancer landscape? In a recent study, published in JAMA Oncology, researchers evaluated whether the HER2DX assay could predict ... Researchers of a study, published in Radiotherapy and Oncology, evaluated the effects of post-mastectomy radiation ...